SENP-1 Inhibitor Compositions for Alpha-Synuclein Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods to treat or prevent neurodegenerative diseases such as Parkinson's disease by targeting specific biological molecules associated with their pathological conditions.
Innovation Solution
The use of Sentrin-specific protease 1 (SENP-1) inhibitors, such as small ubiquitin-like modifier 2 (SUMO-2) aldehyde, momordin lc, streptonigrin, hinokiflavone, and siRNAs of SENP-1, to treat or prevent neurodegenerative diseases by increasing neurons, reducing SENP-1, and modulating SUMO-1 levels in the brain, thereby mitigating symptoms and progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SENP-1 inhibitors are administered to treat neurodegenerative diseases, then neuronal damage and protein aggregates are reduced, but the complexity of the treatment regimen increases
Solution Approach 1:
The treatment approach is segmented by identifying and targeting the specific enzyme SENP-1 that processes alpha-synuclein. By focusing on this single enzymatic target rather than general neuroprotection, the treatment achieves specificity and effectiveness while maintaining a relatively simple administration protocol.
Solution Approach 2:
The invention changes the biochemical parameter of SENP-1 enzyme activity through inhibition. By modulating this specific enzymatic parameter, the treatment effectively reduces toxic alpha-synuclein processing and protein aggregate formation, improving treatment reliability through precise biochemical control.
2Reliability
If SENP-1 inhibitors are used to reduce protein aggregates and oxidative stress, then neurological deficits are reversed, but the cost and accessibility of treatment may be limited
Solution Approach 1:
The SENP-1 inhibitor acts as an intermediary molecule that blocks the harmful enzymatic activity. This small molecule mediator can be administered systemically and crosses the blood-brain barrier to reach the target enzyme, providing effective treatment while maintaining relatively simple manufacturing and administration requirements compared to gene therapy or cell-based approaches.
Data Source
AI summary
The present invention provides methods for treating a neurodegenerative disease in a subject, preventing a neurodegenerative disease in a subject, increasing neurons in a region of the brain of a subject, increasing small ubiquitin-like modifier 1 (SUMO-1) in a region of the brain of a subject, reducing Sentrin-specific protease 1 (SENP-1) in a region of the brain of a subject, reducing Serine 129 phosphorylated alpha-synuclein in a region of the brain of a subject, reducing SENP-1 nuclear translocalization from the cytosol and/or reducing protein aggregates in a region of the brain of a subject. The method comprises administering to the subject an effective amount of a pharmaceutical composition comprising a specific SENP-1 inhibitor. The specific SENP-1 inhibitor may be selected from the group consisting of SUMO-2 aldehyde, momordin lc, streptonigrin, hinokiflavone, siRNA of SENP-1, and a combination thereof. Also provided is the pharmaceutical composition.